Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
68
ATHA Quote, Financials, Valuation and Earnings
Last price:
$6.92
Seasonality move
:
10.45%
Day range:
$6.37 - $7.25
52-week range:
$2.20 - $8.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.03x
Volume:
1.4M
Avg. volume:
2.1M
1-year change:
27.19%
Market cap:
$27.5M
Revenue:
--
EPS (TTM):
-$7.55
Analysts' Opinion
-
Consensus RatingAthira Pharma, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $4.00, Athira Pharma, Inc. has an estimated downside of -42.61% from its current price of $6.97.
-
Price Target UpsideAccording to analysts, the highest upside price target is $4.00 representing -100% upside increase from its current price of $6.97.
Fair Value
-
According to the consensus of 2 analysts, Athira Pharma, Inc. has -42.61% downside to fair value with a price target of $4.00 per share.
ATHA vs. S&P 500
-
Over the past 5 trading days, Athira Pharma, Inc. has overperformed the S&P 500 by 79.92% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Athira Pharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Athira Pharma, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Athira Pharma, Inc. reported revenues of --.
Earnings Growth
-
Athira Pharma, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Athira Pharma, Inc. reported earnings per share of -$1.68.
Enterprise value:
3.2M
EV / Invested capital:
0.11x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-0.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$929K
Return On Assets:
-74.22%
Net Income Margin (TTM):
--
Return On Equity:
-95.01%
Return On Invested Capital:
-92.41%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$1.1M | -$972K | -$929K | -$243K | -$243K | |
| Operating Income | -$119.4M | -$111.9M | -$39.3M | -$25.5M | -$6.9M | |
| EBITDA | -$118.3M | -$110.9M | -$38.3M | -$25.3M | -$6.6M | |
| Diluted EPS | -$3.18 | -$2.85 | -$7.55 | -$0.75 | -$1.68 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $239M | $229M | $178.5M | $82M | $27M | |
| Total Assets | $347.3M | $274.2M | $184.7M | $86.2M | $30M | |
| Current Liabilities | $9.4M | $10.3M | $28.6M | $27.8M | $2.8M | |
| Total Liabilities | $11.1M | $11.9M | $29.9M | $28.7M | $3.2M | |
| Total Equity | $336.2M | $262.2M | $154.8M | $57.6M | $26.8M | |
| Total Debt | $1.7M | $1.7M | $1.3M | $912K | $460K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$90.1M | -$97.5M | -$52.3M | -$23M | -$4.7M | |
| Cash From Investing | $113.3M | $64M | -$4.1M | $18M | $5.7M | |
| Cash From Financing | $488K | $312K | $58K | $12K | -- | |
| Free Cash Flow | -$90.4M | -$97.5M | -$52.3M | -$23M | -$4.7M | |
ATHA
Sector
Market Cap
$27.5M
$27.9M
Price % of 52-Week High
83.37%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
0.25%
-1.49%
1-Year Price Total Return
27.19%
-16.66%
Beta (5-Year)
2.948
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.67
200-day SMA
Buy
Level
$3.62
Bollinger Bands (100)
Buy
Level
3.61 - 4.57
Chaikin Money Flow
Sell
Level
-59.6M
20-day SMA
Buy
Level
$4.39
Relative Strength Index (RSI14)
Buy
Level
83.91
ADX Line
Buy
Level
23.83
Williams %R
Neutral
Level
-30.4831
50-day SMA
Buy
Level
$4.26
MACD (12, 26)
Buy
Level
0.32
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
80.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-13.2693)
Sell
CA Score
(Annual)
Level (-3.0762)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (14.0442)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
Stock Forecast FAQ
In the current month, ATHA has received 0 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ATHA average analyst price target in the past 3 months is $4.00.
-
Where Will Athira Pharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Athira Pharma, Inc. share price will drop to $4.00 per share over the next 12 months.
-
What Do Analysts Say About Athira Pharma, Inc.?
Analysts are divided on their view about Athira Pharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Athira Pharma, Inc. is a Sell and believe this share price will rise from its current level to $4.00.
-
What Is Athira Pharma, Inc.'s Price Target?
The price target for Athira Pharma, Inc. over the next 1-year time period is forecast to be $4.00 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ATHA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Athira Pharma, Inc. is a Hold. 2 of 2 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ATHA?
You can purchase shares of Athira Pharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Athira Pharma, Inc. shares.
-
What Is The Athira Pharma, Inc. Share Price Today?
Athira Pharma, Inc. was last trading at $6.92 per share. This represents the most recent stock quote for Athira Pharma, Inc.. Yesterday, Athira Pharma, Inc. closed at $6.97 per share.
-
How To Buy Athira Pharma, Inc. Stock Online?
In order to purchase Athira Pharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ATHA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ATHA
Sector
P/E ratio
--
23.85x
PEG ratio
-0.01x
-0.01x
P/B ratio
1.03x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
ATHA
Sector
Revenue growth
--
4.62%
Earnings growth
-124.65%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
ATHA
Sector
Profitability FY 2024
-$970K
$3.6M
Return on invested capital
-92.41%
-31.87%
Return on assets
-74.22%
-28.18%
Return on equity
-95.01%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
ATHA
Sector
Total cash
$25.2M
$26.4M
Short term investments
$2.8M
$25.7M
Total assets
$58.8M
$76.9M
Long term debt
$460K
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
